HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines.
about
Avian Influenza Viruses, Inflammation, and CD8(+) T Cell ImmunitySeasonal influenza vaccination and technologies.Development of stable influenza vaccine powder formulations: challenges and possibilitiesNewcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.Kinetics of influenza A virus infection in humans.Assessment of markers of the cell-mediated immune response after influenza virus infection in frail older adults.Influenza vaccine responses in older adults.Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccineCerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onsetHumoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant.Active immunization against virus infections due to antigenic drift by induction of crossreactive cytotoxic T lymphocytesSequential infection or immunization of ferrets with a series of influenza A (H3N2) strains (report to the Medical Research Council's Sub-Committee on influenza Vaccines (CDVIP/IV)).Immunological principles and emerging strategies of vaccination for the elderly.Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine.Increased immunogenicity of inactivated influenza virus vaccine containing purified surface antigen compared with whole virus in elderly women.Analysis of human antiviral cytotoxic T-lymphocyte responses for vaccine trials using cryopreserved mononuclear leukocytes: demonstration of feasibility with influenza virus-specific responsesX-linked lymphoproliferative syndrome. Natural history of the immunodeficiency.Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults.Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response.Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines.Human influenza vaccines and assessment of immunogenicity.Improving immunogenicity and effectiveness of influenza vaccine in older adults.Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults.Connecting within-host dynamics to the rate of viral molecular evolution.Advances in influenza virus vaccine research.Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses.Mathematical model of the primary CD8 T cell immune response: stability analysis of a nonlinear age-structured system.Influenza A virus-specific cytotoxic T lymphocyte activity declines with advancing age.Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms).Repeated influenza vaccination of healthy children and adults: borrow now, pay later?
P2860
Q26765927-C9DB36DE-6CE2-4316-B70F-55350D291831Q30360897-D1FA3FB0-A67C-4274-AE45-ED5D989762E0Q30368221-8C003CE7-C121-4DAB-A252-0C1B880D8AAAQ30382650-96C03517-74DF-456A-94E0-9C9463F75FAEQ30445615-28C953F8-B209-4622-86A9-D61227072D11Q33999622-602C27FB-34F4-42D9-875E-B9A6AE918206Q34705027-7A0D8EE9-32C9-440A-ABA3-329E8084605BQ35866636-0BAAE3A6-5037-461B-A4AA-668BFD519644Q36052900-086C3B27-8615-483B-9712-15C5DAFC4C58Q36057500-D03E3DA2-D6BC-4B26-9B09-FFDEE95F8340Q36356008-B16DF2B0-211C-4E73-B69D-F317ECC23545Q36472674-E62A2153-BF99-4040-BC56-3A4BC3346875Q36728309-BF095543-AB33-47A1-8AC4-284EE142588BQ36737727-F7F398FE-F697-4A38-94F0-77E3CA53BC8DQ36927062-91B7503B-EFC8-4630-A10C-6F604322DD6EQ36930653-CD3A9A74-B39D-4542-9610-22ECAFE397D9Q36990192-94C56A4A-3EBF-4380-B93C-EE7BA6715749Q37192504-FBA262CD-17D0-4330-9054-ABF3C22A3F2FQ37461377-B094EE29-7BFF-4670-A627-1C1B2C63048BQ37655007-DFFCAEB3-98AB-4117-984B-B8653CBD3B08Q37812125-F76CEE36-F6B2-4B8B-9BC0-F9B3AC19C3D1Q37951523-A46B860B-B924-4E08-B62E-A7D1B3030166Q38124061-81897F31-2950-4407-A566-64656B3BBC20Q40520879-D9302134-A7FF-4B5B-996E-3DE089101574Q40841606-DEB23690-86C8-4122-91AD-E2C4CD38674EQ43598183-4B58951F-8A02-42B0-AB99-C86A9B969E0FQ45237943-BF261C5E-CD21-49D2-BDC0-7A655917C4A8Q45774268-54F0F374-9F66-4D5A-899E-1B260A6397B2Q45832945-2AF58DEE-CCFC-4F0A-9716-B05A362FC295Q50775600-7BE6B3C8-C063-412C-9B63-F6302907D6DE
P2860
HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh-hant
name
HLA restricted virus-specific ...... nactivated influenza vaccines.
@en
HLA restricted virus-specific ...... nactivated influenza vaccines.
@nl
type
label
HLA restricted virus-specific ...... nactivated influenza vaccines.
@en
HLA restricted virus-specific ...... nactivated influenza vaccines.
@nl
prefLabel
HLA restricted virus-specific ...... nactivated influenza vaccines.
@en
HLA restricted virus-specific ...... nactivated influenza vaccines.
@nl
P2093
P1433
P1476
HLA restricted virus-specific ...... nactivated influenza vaccines.
@en
P2093
C W Potter
G C Schild
P304
P356
10.1016/S0140-6736(81)91389-1
P407
P577
1981-10-01T00:00:00Z